Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07382752 · ClinicalTrials.gov registry record
Decoupling Immunotherapy Toxicity and Cancer Response
A clinical trial of Tumor and Cardiovascular, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 1
- Study location
NCT07382752 is a study of Tumor and Cardiovascular that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,200 participants, above the 118-participant average among 18 other Tumor trials with a reported enrollment target (917% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07382752, a study of Tumor and Cardiovascular, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Conditions Studied
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2030-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07382752
The ClinicalTrials.gov registry entry for NCT07382752 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 18 other Tumor trials with a reported enrollment target (917% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT07382752 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07382752 about?
NCT07382752 is a clinical study titled "Decoupling Immunotherapy Toxicity and Cancer Response". This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
What is the current status of trial NCT07382752?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2026-01-09. Estimated completion is 2030-06-30.
What conditions does trial NCT07382752 study?
This clinical trial studies the following conditions: Tumor, Cardiovascular.
Who is sponsoring clinical trial NCT07382752?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07382752 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Live Tumor Fragments of Surgical Resections
RECRUITING
-
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.